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Abstract
Background: Immunohistochemical detection of prostate specific antigen (PSA) is widely used to
identify metastatic prostatic adenocarcinoma. However, PSA may not be expressed in some poorly
differentiated prostatic carcinomas and its immunoreactivity has been found in some non-prostatic
tissues. P501s (prostein) is a prostate-specific marker that is expressed in the cytoplasm of benign
and malignant prostatic glandular cells. It has not been detected in any other normal or malignant
tissues. The purpose of this study was to evaluate the expression of P501s in metastatic prostatic
adenocarcinoma and compare its expression with PSA.
Methods: Immunohistochemical stains with anti-P501s antibodies were performed on 5-micron
sections of tissue microarray (TMA) specimens. The TMA is constructed with normal donor
prostates (NDP), prostatic adenocarcinoma (PRCA), non-neoplastic prostatic tissues adjacent to
malignant glands (NAT), benign prostatic hyperplasia (BPH), high-grade prostatic neoplasia (PIN),
metastatic adenocarcinoma to lymph nodes (MLN), metastatic adenocarcinoma to other sites
(MC), and samples of benign testis, colon, adrenal and kidney. The two groups of metastatic lesions
were also subjected to stains with antibodies to PSA. A composite score (ranging from 0 to 3) was
assigned to score intensity of staining.
Results: Granular staining pattern of p501s was seen in all benign glands (score = 1.77 – 2.1) and
malignant acini (score = 1.52) at the apical aspect of cytoplasm, predominantly adjacent to the
nuclei. No staining was observed in controls including testis, colon, adrenal and kidney. The MLN
group received a score of 1.0, with 10% of cases negative for p501s. The MC cases had a score of
0.64, with 16.7% of case showing loss of p501s expression. Although the metastatic lesions
demonstrated similar rate of negative expression with PSA antibody, only 2 MC cases (3.3%)
showed simultaneous negative stains for both P501S and PSA.
Conclusion: P501s is an organ specific marker for benign and malignant prostatic epithelial cells.
Its characteristic cytoplasmic stain pattern provides an additional valuable immunomarker for
detection of metastatic prostatic malignancy, even though the intensity of its expression is reduced,
as in the case with PSA. Simultaneous stains with P501S and PSA will greatly improve the detection
rate and identify a significant majority of the metastases.
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Background
Prostatic adenocarcinoma is the most prevalent form of
cancer in men and the second leading cause of cancer
death in the United States [1,2]. The patient's death is
often due to local or distal lymph node involvement and
distant metastasis [3]. The metastasis can be the first pres-
entation in some patients without previous diagnosis of
prostatic adenocarcinoma [4]. In many patients, the pros-
tatic carcinoma is either impalpable or encountered inci-
dentally after transurethral resection for benign prostatic
hyperplasia [5,6], in which situation the patients may
potentially have metastases without knowing the presence
of prostatic primary. Therefore, in surgical pathology prac-
tice, a metastatic prostatic adenocarcinoma is always
included in the differential diagnosis when encountering
a male patient with metastatic adenocarcinoma of
unknown origin.
Immunohistochemical staining with prostate specific
antigen (PSA) is widely used to aid in the diagnosis of
metastatic prostatic carcinoma. However, PSA may not be
expressed in all cases of prostatic adenocarcinoma [7],
especially in some poorly differentiated prostatic carcino-
mas or metastatic carcinoma [8-11]. Prostatic acid phos-
phatase (PAP) did not show better sensitivity than PSA in
this regard [12,13]. In addition, immunoreactivity of PSA
has been found in some non-prostatic tissues [14-17].
P501s (prostein) is a prostate-specific marker that is
expressed in the cytoplasm of benign and malignant pro-
static glandular cells [18-21]. Prostein is a 553 amino acid
protein which contains 11 potential transmembrane
spanning domains [21]. It has not been detected in any
other normal or malignant tissues [19,21]. There is no
correlation between prostein gene expression and the pro-
static carcinoma Gleason score [21]. Further, no gross dif-
ference in the level of protein expression between primary
and metastatic prostatic carcinomas is observed [21].
These features of prostein may make it a good immuno-
histochemical marker for identification of metastatic
prostate adenocarcinoma. The purpose of this study was
to further characterize the p501s staining features, espe-
cially in metastatic prostatic adenocarcinoma, and to
compare its expression with PSA for the diagnosis of met-
astatic prostate carcinoma.
Methods
Construction of Tissue Microarray Blocks
Tissue microarray (TMA) blocks were created from speci-
mens retrieved from the surgical pathology archives of the
University of Pittsburgh Medical Center. There were 24
cases of normal donor prostates (NDP), 135 of acinar type
of prostatic adenocarcinoma (PCA), 36 of non-neoplastic
prostatic tissues adjacent to malignant glands (NNT), 35
of benign prostatic hyperplasia (BPH), 35 of high-grade
prostatic intraepithelial neoplasia (PIN), 36 of metastatic
adenocarcinoma to lymph nodes (MLN), and 24 of meta-
static carcinoma to other sites (MC). In addition, samples
of benign testis, colon, adrenal and kidney were also
included (n = 6 each). TMA blacks were constructed from
multiple paraffin-embedded tissue blocks by sampling a
specific region from each block in the form of a cylindrical
core and then assembling these tissue cores from the dif-
ferent donor blocks into a new composite paraffin block,
as previously described [22]. To address the tissue hetero-
geneity, four core samples were taken from each paraffin-
embedded tissue specimen.
Immunohistochemistry
Immunohistochemical stains were performed on five-
micron sections of TMA blocks. The sections of all the
groups were deparaffinized and rehydrated through a
graded series of ethanol. Heat induced epitope retrieval
was performed using decloaker, followed by rinsing in
TBS buffer for 5 minutes. Slides were then loaded on Dako
Autostainer. The primary anti-p501s (working dilution
1:400) was a monoclonal mouse antibody (Clone 10E3,
Code M3615) for DakoCytomation (Dako North Amer-
ica, Inc., Carpinteria, CA, USA). The immunolabeling pro-
cedures were carried out according to manufacturers'
instruction using Dako Envision Labelled Polymer-HRP
anti-mouse/anti rabbit (Dako, Glostrup, Denmark).
Slides were then counterstained in hematoxylin and cov-
erslipped.
The two groups of metastatic lesions were also subjected
to immunohistochemical stains as described above with
antibodies to PSA, which was a pre-diluted ready-to-use
rabbit polyclonal antibody (Code N1517) for DakoCyto-
mation (Dako North America, Inc., Carpinteria, CA,
USA). A prostate optimization MRA block was used as
positive control for each antibody.
Interpretation of immunohistochemical stains
In scoring the expression of p501s and PSA, both the
extent and intensity of immonopositivity were consid-
ered, using a method similar to Zhao, et al [23]. The inten-
sity of positivity was scored from 0 to 3 as follows: 0 as
non-stained, 1 as weak, 2 as moderate, and 3 as strong as
positive control. The percentage of positively stained cells
for each staining-intensity was estimated. The final com-
posite score was determined after multiplying the inten-
sity of positivity and percentage of positivity in the
respective lesions. For example, if 50% of tumor cells are
scored 1, 25% scored 2, and the remaining 25% scored 3,
the composite staining score of this case is [50% × 1] +
[25% × 2] + [25% × 3] = 1.75. Two board certified pathol-
ogists evaluated the specimens of this study. The data was
presented as mean ± standard errors (SE).Diagnostic Pathology 2007, 2:41 http://www.diagnosticpathology.org/content/2/1/41
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Results
Immunohistochemical analysis using anti-p501s anti-
bodies was performed in benign and malignant epithelial
cells of prostate. A granular staining at the apical aspect of
cytoplasm, predominantly adjacent to the nuclei, was
observed (Figure 1A–E, ), corresponding to the location of
Golgi complex[21]. In weakly stained cases, the granules
can be relatively faint and punctuate, but still be visible in
the apical region of the cells using higher magnifications.
The staining scores for NDP, BPH and PIN were 1.95 ±
0.15, 2.1 ± 0.8 and 2.09 ± 0.1, respectively (Figure 2A).
None of the cases from the three groups were negative for
p501s. The non-neoplastic tissues adjacent to malignant
glands (NNT) received a score of 1.77 ± 0.13 (Figure 2A),
with 5.6% of the cases showing loss of p501s expression
(Figure 2B). The mean score for PCA cases was 1.52 ±
0.06, which was not significantly different from that of the
above non-neoplastic groups. In the PCA group, 5.9% of
cases were negative for p501s (Figure 2B). The prostatic
ductal carcinoma demonstrated a similar p501s-staining
pattern (Figure 1E). No staining was seen in samples of
testis, colon, and kidney (Figures 1F–1H). Some adrenal
tissues revealed a very weak, smudge, and non-granular
cytoplasmic staining, which was considered non-specific
(Figure 1I).
Metastatic prostatic carcinomas also demonstrate a granu-
lar apical staining pattern with p501s antibody (Figures
3A and 3B). The mean scores of p501s staining in the
MLN and MC groups were 1.0 ± 0.1 and 0.64 ± 0.11 (Fig-
ure 4A), respectively, which were statistically lower than
those of the above benign and malignant epithelium of
prostate per se (p < 0.05) (see Table 1 for the summary of
p501s staining scores). Negative p501s staining was seen
in 3 of 30 MLN cases (10%) and in 4 of 24 MC cases
Scores of p501s expression and percentage of cases negative  for p501s Figure 2
Scores of p501s expression and percentage of cases 
negative for p501s. A. Mean scores of p501s immunohisto-
chemical expression in benign and malignant prostatic epithe-
lium. NDP: normal donor prostate. NNT: non-neoplastic 
prostatic tissues adjacent to malignant glands of prostatic 
adenocarcinoma. BPH: benign prostatic hyperplasia. PIN: 
high-grade prostatic intraepithelial neoplasia. PCA: prostatic 
adenocarcinoma. B. Percentage of cases of each group that 
were negative for p501s staining.
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Immunohistochemical expression of p501s on benign and  malignant epithelium of prostate and non-prostatic tissues Figure 1
Immunohistochemical expression of p501s on benign 
and malignant epithelium of prostate and non-pros-
tatic tissues. A. Non-neoplastic prostatic tissue adjacent to 
malignant glands (NNT). B. Benign prostatic hyperplasia. C. 
High-grade prostatic intraepithelial neoplasia (PIN). D. Pros-
tatic adenocarcinoma (PCA).
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(16.7%) (Figure 4B). P501s negativity was found in 13%
of all metastatic lesions (combined MLN and MC).
Loss of PSA expression was observed in 2 of 30 MLN cases
(6.7%) and in 5 of 24 MC cases (20.8%) (Figure 4A). In
the PSA immunoreactive metastatic lesions, a denser dif-
fuse cytoplasmic PSA staining was seen (Figures 3B and
3D). As a result of the diffusing staining pattern of PSA,
the mean scores of PSA from the metastatic lesions were
slightly higher than those with p501s antibody (1.66 ±
0.15 for MLN and 1.22 ± 0.18 for MC, respectively) (Fig-
ure 4B). However, it was clear that different staining pat-
terns were present when comparing the two antibodies.
Some of the MC cases were negative for p501s, but posi-
tive for PSA (Figures 3E and 3F). In contrast, some MC
cases were negative for PSA, but immunoreactive for
p501s (Figures 3G and 3H). In high-grade metastatic car-
cinoma, the p501s stain may be weak and punctuated
(Figure 3F). None of MLN cases showed loss of both
p501s and PSA. Simultaneous negative stains for both
p501s and PSA were seen in only 2 MC cases (5.6%),
which comprised 3.3% of all metastatic lesions.
Discussion
P501s (prostein) is an organ specific marker for benign
and malignant prostatic epithelial cells. The previous and
current studies did not find the p501s expression in any
other organ systems at both mRNA and protein levels
[19,21]. This makes p501s a great candidate for the devel-
opment of new diagnostic as well as prostein-specific anti-
body and T-cell based therapeutic strategies against
prostatic carcinoma [20]. The staining pattern of p501s
was granular discoloration at the apical aspect of cyto-
plasm of epithelial cells, which was thought to correspond
to the Golgi complex [21]. Therefore, in addition to its
organ specificity, the characteristic stain pattern of pros-
tein provides an additional valuable immunomarker for
detection of metastatic carcinoma of prostatic primary.
Scores of p501s and PSA expression in metastatic prostatic  lesions (A) and percentage of cases negative for p501s and  PSA stains (B) Figure 4
Scores of p501s and PSA expression in metastatic 
prostatic lesions (A) and percentage of cases nega-
tive for p501s and PSA stains (B). MLN: metastatic pros-
tatic carcinoma to lymph nodes. MC: metastatic prostatic 
carcinoma to other sites.
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Immunohistochemical expression of p501s and PSA on meta- static prostatic carcinoma Figure 3
Immunohistochemical expression of p501s and PSA 
on metastatic prostatic carcinoma. A and C are sec-
tions of metastatic prostatic carcinoma to lymph node (MLN) 
from the same TMA block. B and D are sections of meta-
static prostatic carcinoma to other sites (MC) from the same 
TMA block. Panels E and F are sections from the same MC 
TMA block; panels G and H are from another MC TMA 
block.Diagnostic Pathology 2007, 2:41 http://www.diagnosticpathology.org/content/2/1/41
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However, in some cases, the p501s-stained granules can
be relatively faint and punctuate, we suggest that high-
power examination is necessary to rule out focal staining.
In the metastatic prostatic lesions, the staining intensity of
p501s was reduced. Likewise, the loss of p501s expression
was seen in a small proportion of the metastatic lesions.
This phenomena was also observed in previous studies
with PSA stains [8-11], but argued against the previous
statements made by Kalos and coworkers in this regard
[21]. It was found that PSA immunoreactivity declined
from benign epithelium to PIN and prostatic adenocarci-
noma, suggesting that PSA is regulated differentially and
decreased in expression with malignant transformation
[10]. The mechanisms responsible for the diminished
expression of p501s in metastatic prostatic carcinomas are
unknown, but could be similar to those for PSA. Interest-
ingly, there was a trend of decreased p501s expression in
the groups of primary prostatic carcinoma (PCA) and
non-neoplastic prostatic tissue adjacent to malignant
glands (NNT) (Figure 2), although no statistical differ-
ences were identified compared with groups of NDP, BPH
and PIN. Since no Gleason score was given to the meta-
static lesions, it was possible that metastatic carcinomas
represent higher-grade cancers. As a result of loss of p501s
expression in some metastatic lesions, use of p501s alone
did not offer a significant advantage in identifying the
metastatic tumors when comparing with the use of PSA
alone. However, simultaneous stains with P501S and PSA
largely improved the detection rate and identify a signifi-
cant majority of the metastases. In fact, only 2 cases (3%)
were concurrently negative for both p501s and PSA. This
increases the diagnostic utility of using these immunos-
tains when used together in the assessment of an
unknown primary, possibly of a prostatic origin. Recently,
Netto and his coworkers also concluded that the combi-
nation of PSA and p501s is better than either alone in con-
firming prostate origin in work-up of metastatic or locally
advanced lesions [24].
Conclusion
P501s is an organ specific marker for benign and malig-
nant prostatic epithelial cells. Its characteristic cytoplas-
mic stain pattern provides an additional valuable
immunomarker for detection of metastatic prostatic
malignancy, even though the intensity of its expression is
reduced, as in the case with PSA. Simultaneous stains with
P501S and PSA will greatly improve the detection rate and
identify a significant majority of the metastases. Our study
highlights the importance of including P501s in a diag-
nostic immunostaining panel when the differential diag-
nosis includes a poorly differentiated carcinoma of an
unknown primary and may play in pivotal role in the
diagnosis of such lesions.
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